Author: Lyngbakken, Magnus Nakrem; Berdal, Jan-Erik; Eskesen, Arne; Kvale, Dag; Olsen, Inge Christoffer; Rueegg, Corina Silvia; Rangberg, Anbjørg; Jonassen, Christine Monceyron; Omland, Torbjørn; Røsjø, Helge; Dalgard, Olav
Title: A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics Cord-id: hmfmkosn Document date: 2020_10_20
ID: hmfmkosn
Snippet: Here, we randomized 53 patients hospitalized with coronavirus disease 2019 (COVID-19) to hydroxychloroquine therapy (at a dose of 400 mg twice daily for seven days) in addition to standard care or standard care alone (ClinicalTrials.gov Identifier, NCT04316377). All severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive patients 18 years of age or older were eligible for study inclusion if they had moderately severe COVID-19 at admission. Treatment with hydroxychloroquine did not
Document: Here, we randomized 53 patients hospitalized with coronavirus disease 2019 (COVID-19) to hydroxychloroquine therapy (at a dose of 400 mg twice daily for seven days) in addition to standard care or standard care alone (ClinicalTrials.gov Identifier, NCT04316377). All severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive patients 18 years of age or older were eligible for study inclusion if they had moderately severe COVID-19 at admission. Treatment with hydroxychloroquine did not result in a significantly greater rate of decline in SARS-CoV-2 oropharyngeal viral load compared to standard care alone during the first five days. Our results suggest no important antiviral effect of hydroxychloroquine in humans infected with SARS-CoV-2.
Search related documents:
Co phrase search for related documents- active viral replication and lod detection limit: 1
- acutely ill and logistic regression: 1, 2, 3, 4, 5, 6, 7
- admission sars positive test and logistic regression: 1
Co phrase search for related documents, hyperlinks ordered by date